actus

Last updated on 16 March 2026

Main points

This is a non-randomised, multicentre study comparing two parallel groups, initially comprising 40 HIV-positive subjects and 20 HIV-negative subjects.

Following the signing of the informed consent form and verification of inclusion criteria, participants in the ANRS EP46 NOVAA study are enrolled in the study:

  • 40 HIV-positive subjects enrolled in Infectious Diseases departments
  • 20 HIV-negative subjects enrolled in Travel Medicine departments

Assessment will take place at M156 (+/- 18 months), i.e. more than 10 years after vaccination.

Study type

Category 2, multicentre interventional research comparing two parallel groups of 40 HIV-positive and 20 HIV-negative subjects included in the ANRS EP46 NOVAA study.

Study objectives

To determine vaccine responses by measuring neutralising antibody titres using long-term PRNT neutralisation tests in participants of the ANRS EP46 NOVAA study, people living with HIV (PLHIV) and vaccination-naïve controls 156 months after primary yellow fever vaccination.

Note:

  • To determine vaccine responses by measuring neutralising antibody titres using AcN 400 pseudo–type neutralisation tests.
  • To identify clinical and biological factors predictive of a sustained vaccine response.